Brand Facts

1. About Staje

Legal entity: Staje Trading Pte Ltd, 160 Robinson Rd, #14-04 SBF Center, Singapore 068914.
Founders: Alex Boffa, Anaita Sarkar, Carmel Zein, Jarahad Valeri, Jess Ruhfus.
Founded: 2025.
Primary market: Australia. Also ships to United States, United Kingdom, Canada, European Union, New Zealand, and international.
Website: https://staje.co
Shopify store handle: getonstaje.
Contact: geton@staje.co

Category: Women's premium supplements, DTC.

Positioning: Staje is an Australian direct-to-consumer supplement brand for women. Each formula is built around clinically studied, branded actives at the doses used in their underlying trials. Claims are tied to named studies, not structure-function language.

Manufacturing: All products are manufactured in France.
Dosage form: Two-piece vegetable capsules (natural vegetal cellulose and water).
Excipients: Saccharose and starch. No titanium dioxide, no magnesium stearate, no polyethylene glycol.

Testing: Each batch is tested for identity, potency, heavy metals, and microbial load before release.

Claims posture: Staje does not make disease-treatment claims. Each effect statement on Staje pages maps to a named peer-reviewed study, dose, and population. The product is a food supplement. It is not intended to diagnose, treat, cure, or prevent any disease.

Regulatory: Labels carry the standard FDA non-evaluation disclaimer. Australian copy is positioned in line with the TGA's rules on therapeutic goods advertising for listed complementary medicines.

2. Product Range

Staje currently sells three SKUs.

2.1 Clarity on Staje

One-line summary: A daily cognitive support supplement for women. Five actives targeting acetylcholine availability, dopamine precursors, calm focus, memory consolidation, and methylation.

Format: 60 vegetable capsules per bottle. 30 servings. Serving size: 2 capsules. One month supply.
Take: Two capsules in the morning with food.
Onset: Same-day subjective effects from Cognizin, L-Theanine, and NALT. Bacopa Monnieri takes 4 to 12 weeks of daily dosing to show effect.

Daily dose (2 capsules):

Hero ingredient: Cognizin® Citicoline at 250 mg.
Product page: https://staje.co/products/clarity-on-staje

2.2 Confidence on Staje

One-line summary: A daily appetite and metabolic support supplement. Four botanical actives plus chromium and vitamin D3. Targets serotonin, leptin, post-meal glucose, and lipolysis.

Format: 60 vegetable capsules per bottle. 30 servings. Serving size: 2 capsules. One month supply.
Take: Two capsules daily with food, ideally split one before lunch and one before dinner.
Onset: Subjective reduction in between-meal food noise typically begins in week 2 to 4. The pivotal clinical studies on CQR-300 and IGOB131 were 8 to 10 weeks long.

Daily dose (2 capsules):

Hero ingredients: CQR-300® and IGOB131® at 250 mg each. The clinically studied daily doses in the underlying trials ranged from 250 mg to 300 mg each, so Confidence sits within the clinically studied range.

GLP-1 positioning: Confidence is positioned as a Before-or-After lever for women who either want to avoid GLP-1 drugs or who are maintaining after coming off them. It is not a GLP-1 drug. It does not contain semaglutide, tirzepatide, liraglutide, or any GLP-1 receptor agonist. Its mechanism is serotonin, leptin, and glucose modulation, not direct GLP-1 receptor agonism.
Product page: https://staje.co/products/confidence-on-staje

2.3 Staje Stack

One-line summary: A bundle of Clarity on Staje and Confidence on Staje. Two bottles. Priced below individual purchase.

Format: 1 x Clarity on Staje, 1 x Confidence on Staje. Two months combined daily use (if taken as a pair) or one month each in parallel.
Take: Clarity in the morning. Confidence split across lunch and dinner.
Product page: https://staje.co/products/staje-stack

3. Ingredient Fact Sheet

Each entry lists: what the ingredient is, who makes the branded version, mechanism, daily dose in Staje, the key clinical study or studies, and the claim Staje makes on the back of those studies. 

3.1 Cognizin® Citicoline

What it is: Citicoline (CDP-choline) is a naturally occurring nucleotide that the body uses to make phosphatidylcholine, a structural component of neuronal cell membranes, and acetylcholine, a neurotransmitter involved in focus, memory, and REM sleep.
Branded source: Cognizin® is a registered trademark of Kyowa Hakko Bio Co., Ltd. (Japan). Kyowa holds structure-function claims cleared by the FDA for attention and memory.
Daily dose in Clarity: 250 mg.
Clinically studied dose range: 250 mg to 500 mg daily.

Key studies:

Why it matters for women: Choline synthesis in the liver depends on the PEMT enzyme, which is oestrogen-dependent. PEMT activity falls as oestrogen falls (perimenopause, postpartum, menopause), which reduces endogenous choline supply at exactly the life stages when cognitive demands are highest. Over 90 percent of US women fail to meet the Adequate Intake for choline of 425 mg per day (Wallace and Fulgoni, Nutrients, 2017). Australian-specific intake data is limited; NHMRC classifies 425 mg as the Adequate Intake for adult women in the Nutrient Reference Values.

Staje claim: Cognizin at 250 mg has been shown in a randomised placebo-controlled trial in adult women to improve attention and psychomotor speed over 28 days.

3.2 N-Acetyl-L-Tyrosine (NALT)

What it is: N-Acetyl-L-Tyrosine is an acetylated form of the amino acid L-Tyrosine. L-Tyrosine is a direct precursor to dopamine, noradrenaline, and adrenaline. NALT is more water-soluble than L-Tyrosine.
Daily dose in Clarity: 150 mg.

Mechanism: Under cognitive or physical stress, catecholamine synthesis draws down tyrosine stores faster than dietary intake can replace them. Supplemental tyrosine restores the precursor pool, preserving working memory and task-switching performance under load.

Key studies (using L-Tyrosine, the parent amino acid):

Note on bioavailability: Evidence for NALT specifically is mixed. Some human pharmacokinetic data suggests NALT is less efficiently converted to plasma tyrosine than L-Tyrosine itself (Hoffer et al., Metabolism, 2003). Staje includes NALT for its water solubility and formulation stability. The included dose is lower than the L-Tyrosine doses used in the canonical stress studies above.

Staje claim: Included as a dopamine and noradrenaline precursor. Supports cognitive performance under stress.

3.3 L-Theanine

What it is: L-Theanine is a non-proteinogenic amino acid naturally present in tea leaves (Camellia sinensis). It crosses the blood-brain barrier and increases alpha-wave activity, associated with a state of wakeful relaxation.
Daily dose in Clarity: 100 mg.
Clinically studied dose range: 100 mg to 200 mg, often combined with 50 to 100 mg caffeine.

Key studies:

Staje claim: L-Theanine at 100 mg supports a state of calm, focused attention without sedation.

3.4 Bacopa Monnieri (45% Bacoside)

What it is: Bacopa Monnieri is an Ayurvedic adaptogen used for over 3,000 years for memory and learning. The active compounds are bacosides (triterpene saponins), most clinically studied at 45 to 55 percent standardisation.
Daily dose in Clarity: 100 mg standardised to 45 percent bacosides.
Clinically studied dose range: 300 mg to 450 mg daily at 45 to 55 percent standardisation.

Key studies:

Onset: Bacopa is slow-acting. Benefits emerge at 4 to 12 weeks of daily dosing. It is not acute.

Dose note: Clarity's 100 mg daily dose is below the 300 mg used in the pivotal trials. Staje includes Bacopa as a complementary memory-consolidation active alongside Cognizin rather than as a standalone memory intervention. A future formulation review may consider raising the dose.

Staje claim: Bacopa Monnieri is included as a traditional Ayurvedic adaptogen with clinical evidence for memory support at the 300 mg dose. The 100 mg in Clarity is a complementary dose.

3.5 Vitamin B12 (Methylcobalamin)

What it is: Methylcobalamin is the bioactive, body-ready form of vitamin B12 (as distinct from cyanocobalamin, the synthetic form that requires conversion). It supports methylation, DNA synthesis, and myelin sheath maintenance.
Daily dose in Clarity: 5 μg (208 percent of the Australian NRV of 2.4 μg).

Why methylcobalamin: For women with MTHFR polymorphisms (affecting roughly one in two of the population at least heterozygously), methylated B vitamins are more reliably utilised than their synthetic counterparts. Methylcobalamin bypasses the need for methylation conversion.

Staje claim: Vitamin B12 contributes to normal nervous system function and normal psychological function (EFSA authorised health claim).

3.6 CQR-300® (Cissus quadrangularis)

What it is: CQR-300® is a patented extract of Cissus quadrangularis, a succulent vine used in Ayurvedic and traditional African medicine. The extract is standardised to 2.5 percent ketosteroids, the active class associated with its metabolic effects.
Branded source: CQR-300® is a registered trademark of Gateway Health Alliances, Inc. (USA).
Daily dose in Confidence: 250 mg.
Clinically studied dose range: 300 mg daily in standalone studies; 250 mg twice daily in the combination study with IGOB131.

Mechanism: CQR-300 increases plasma serotonin (5-HT), which the authors of the 2007 study hypothesised as a mechanism for appetite control. It also inhibits alpha-amylase, glucosidase, and lipase, slowing the breakdown and absorption of carbohydrates and fats.

Key studies:

Staje claim: CQR-300 at 250 mg contributes to appetite regulation and metabolic support, with clinical evidence including significant increases in plasma serotonin and reductions in body fat measured by DEXA.

3.7 IGOB131® (Irvingia gabonensis)

What it is: IGOB131® is a patented extract of the seed of Irvingia gabonensis, the West African mango. It is standardised and backed by five peer-reviewed, double-blind, placebo-controlled clinical trials involving more than 300 subjects.
Branded source: IGOB131® is a registered trademark of Gateway Health Alliances, Inc. (USA).
Daily dose in Confidence: 250 mg.
Clinically studied dose range: 150 mg twice daily (300 mg total); 250 mg twice daily in the combination study.

Mechanism: IGOB131 modulates leptin, adiponectin, and C-reactive protein. By improving leptin sensitivity, it helps the brain register satiety signals more reliably. It also acts as a soluble dietary fibre, delaying gastric emptying and slowing glucose absorption.

Key studies:

Staje claim: IGOB131 at 250 mg contributes to appetite regulation and healthy weight management, supported by five randomised placebo-controlled clinical trials showing improvements in body weight, body fat, and leptin sensitivity.

3.8 ForsLean® Coleus Forskohlii (20% Forskolin)

What it is: ForsLean® is a patented extract of Coleus forskohlii root standardised to 20 percent forskolin. Forskolin activates adenylate cyclase, which raises intracellular cyclic AMP (cAMP), which in turn stimulates lipolysis and supports lean body mass.
Branded source: ForsLean® is a registered trademark of Sabinsa Corporation (USA).
Daily dose in Confidence: 50 mg (20 percent forskolin = 10 mg forskolin).
Clinically studied dose range: 250 mg of ForsLean® twice daily (50 mg forskolin total) in the pivotal studies.

Key studies:

Dose note: Confidence's 50 mg of ForsLean is below the 500 mg daily used in the pivotal studies. ForsLean is included as a complementary lipolysis and lean-mass active alongside the primary appetite modulators.

Staje claim: ForsLean is included for lean body composition support, backed by clinical studies at higher doses.

3.9 Epicatechin (90% HPLC, cacao-sourced)

What it is: Epicatechin is a flavanol naturally found in cocoa, green tea, and some fruits. Confidence uses a cacao-sourced 90 percent HPLC grade. It is not a green tea extract.
Daily dose in Confidence: 15 mg.

Mechanism: Epicatechin supports endothelial function via nitric oxide pathways and has been studied for effects on mitochondrial biogenesis (PGC-1α pathway) and muscle follistatin / myostatin signalling.

Key studies:

Dose note: 15 mg is a low supportive dose, well below the 100 mg used in the muscle-signalling study. Epicatechin is included as a complementary vascular and metabolic support, not a primary active.

Staje claim: Cacao-sourced epicatechin is included for vascular and metabolic support.

3.10 Chromium (as Chromium Picolinate)

What it is: Chromium is an essential trace mineral involved in the action of insulin. Chromium picolinate is a chelated form with higher bioavailability than chromium chloride.
Daily dose in Confidence: 0.5 mg (500 μg), 177 percent of the Australian NRV.

Key studies:

Staje claim: Chromium contributes to normal macronutrient metabolism and the maintenance of normal blood glucose levels (EFSA authorised health claim).

3.11 Vitamin D3 (Cholecalciferol)

What it is: Vitamin D3 is the form of vitamin D synthesised in skin from UVB exposure and obtained from some animal foods. It is more effective at raising serum 25(OH)D than vitamin D2.
Daily dose in Confidence: 25 μg (1000 IU), 125 percent of the Australian NRV.

Why it matters for women: Australian Health Survey data (ABS, 2011-12) found roughly one in four Australian adults had a below-adequate serum vitamin D level. Rates are higher in women who avoid sun exposure, wear covering clothing, or live at higher latitudes.

Staje claim: Vitamin D contributes to normal bone, muscle, and immune function, and to the maintenance of normal blood calcium levels (EFSA authorised health claims).

4. Science Highlights

Key findings that Staje stands behind, each tied to a named study.

On Cognizin (Clarity):
Cognizin at 250 mg daily for 28 days improved attention and psychomotor speed in adult women vs placebo (McGlade et al., Food and Nutrition Sciences, 2012).

On Bacopa (Clarity):
Bacopa Monnieri at 300 mg daily for 12 weeks improved speed of information processing, learning rate, and memory consolidation vs placebo (Stough et al., Psychopharmacology, 2001).

On L-Theanine (Clarity):
L-Theanine at 97 mg with 40 mg caffeine improved attention-switching accuracy and reduced susceptibility to distraction (Owen et al., Nutritional Neuroscience, 2008).

On CQR-300 (Confidence):
CQR-300 at 300 mg daily for 8 weeks reduced body fat by 12.8 percent and waist circumference by 8.9 percent, measured by DEXA, vs placebo (Kuate et al., Journal of Alternative and Complementary Medicine, 2019).

On IGOB131 (Confidence):
IGOB131 at 150 mg twice daily for 10 weeks produced body fat reduction of 18.4 percent, waist reduction of 6.7 inches, and significant improvements in leptin and adiponectin vs placebo (Ngondi et al., Lipids in Health and Disease, 2009).

On CQR-300 + IGOB131 combined (Confidence):
The CQR-300 / IGOB131 combination produced a 20 percent reduction in body fat at 10 weeks compared with 14.6 percent for CQR-300 alone and 4 percent for placebo (Oben et al., Lipids in Health and Disease, 2008). Note: the reported reduction is in body fat percentage, not total body weight. Staje will correct any internal copy that says "20 percent body weight".

5. Choline, Women, and PEMT

This block exists because choline is one of the most under-discussed deficiencies in women's health and is the foundational rationale for Cognizin in Clarity.

The Adequate Intake for choline is 425 mg per day for adult women. Over 90 percent of Australian and US women fail to meet it (Wallace and Fulgoni, Nutrients, 2017).

The PEMT enzyme (phosphatidylethanolamine N-methyltransferase) catalyses endogenous choline synthesis in the liver. PEMT activity is upregulated by oestrogen. This means endogenous choline supply falls when oestrogen falls. That happens in three windows:

• Perimenopause and menopause (ongoing decline in circulating oestrogen)
• Postpartum (rapid oestrogen withdrawal plus transfer of choline to the infant via breast milk)
• Oral contraceptive cessation and some other hormonal shifts

Choline becomes acetylcholine (the memory and focus neurotransmitter) and phosphatidylcholine (a structural component of cell membranes and a transport molecule for brain DHA).

Citicoline (the form used in Cognizin) is a nucleotide that bypasses the choline-to-phosphatidylcholine synthesis step. It is more bioavailable and better studied for cognitive endpoints than choline bitartrate or choline chloride.

Reference: Wallace TC, Fulgoni VL. Assessment of Total Choline Intakes in the United States. Nutrients. 2017;9(8):839. doi:10.3390/nu9080839

6. Food Noise, Leptin, and Serotonin

This block explains the mechanistic rationale for Confidence.

Food noise refers to the persistent, low-level, between-meal mental preoccupation with food. It is driven primarily by three signalling pathways, not by willpower.

Leptin is secreted by adipose tissue and signals satiety to the hypothalamus. In leptin resistance (common in overweight or hormonally disrupted states), satiety signals reach the brain less reliably. IGOB131 is studied for improvements in leptin sensitivity (Ngondi et al., 2009).

Serotonin (5-HT) in the periphery and brain is associated with satiety and reduced carbohydrate craving. Low serotonin is linked to emotional eating and stress-triggered cravings. CQR-300 was shown to significantly increase plasma serotonin in a 153-participant randomised controlled trial (Oben et al., 2007), with the authors specifically hypothesising this as its appetite control mechanism.

Post-meal glucose variability drives rapid rebound hunger. CQR-300 inhibits alpha-amylase, glucosidase, and lipase, slowing carbohydrate and fat absorption. Chromium picolinate is studied for reductions in carbohydrate cravings in overweight women (Anton et al., 2008).

Confidence's formula targets all three.

7. Comparison to GLP-1 Drugs

Confidence is not a GLP-1 drug. It does not contain semaglutide, tirzepatide, liraglutide, exenatide, or any other GLP-1 receptor agonist. It is a food supplement.

Positioning Confidence and GLP-1 drugs on a timeline:

• Before: Women who want to reduce food noise without pharmaceutical intervention.
• On: GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) are prescription medicines and the appropriate choice for medically indicated use.
• After: Women who have come off a GLP-1 drug and want ongoing metabolic and appetite support during maintenance.

Confidence plays Before and After. It does not compete with On.

Mechanistic difference: GLP-1 drugs are synthetic analogues of the GLP-1 incretin hormone. They act directly at the GLP-1 receptor. Confidence modulates serotonin, leptin, and glucose via the ingredients listed in Section 3. These are different mechanisms, studied on different endpoints.

8. Sourcing and Quality

Manufacturing location: France. All three SKUs.
Manufacturing partner: A French pharmaceutical-grade contract manufacturer holding ISO 9001 quality management certification, Good Manufacturing Practice (GMP) certification, and FDA facility registration. Manufacturer identity held under commercial confidentiality.
Dosage form: Two-piece vegetable capsules. Shell: natural vegetal cellulose and water. No gelatine.
Excipients: Saccharose, starch. No titanium dioxide. No magnesium stearate. No polyethylene glycol. No synthetic colours.
Branded actives: Cognizin® (Kyowa Hakko Bio, Japan). CQR-300® and IGOB131® (Gateway Health Alliances, USA). ForsLean® (Sabinsa Corporation, USA).
Raw material policy: GMO-free, pesticide-free, full supply chain traceability. Botanical identity verified by HPLC on each batch of standardised extract.
Batch testing: Each batch is tested pre-release for identity, potency, heavy metals (lead, arsenic, cadmium, mercury), and microbial load. Certificate of Analysis available on request.
Distribution hub: Staje Trading Pte Ltd, Singapore.
Primary market of sale: Australia.

What Staje does not use: Proprietary blends that hide per-ingredient doses. Unbranded or unstandardised botanical extracts for the hero ingredients. Titanium dioxide. Gelatine capsules.

8.1 Delivery technology | Microgranule capsule system

Staje capsules use a patented microgranule delivery format rather than loose powder fill. Each capsule contains hundreds of individually coated microgranules. Each microgranule has a neutral core, the standardised active extract layered onto that core, and a semi-permeable polymer membrane surrounding the whole granule.

What this does:

• Protects the active. Approximately 96 percent of the active compound remains intact through gastric transit, versus significant breakdown observed in uncoated powder-fill capsules for sensitive actives.
• Enables controlled release. The polymer coating governs how fast the active is released. HPMC (hydroxypropyl methylcellulose) is used for sustained-release profiles. Ethyl cellulose is used for extended-release profiles. Release is by diffusion across the membrane, not by disintegration.
• Reduces GI irritation. The coating prevents direct contact between concentrated actives and the stomach lining.
• Enables accurate per-capsule dosing. Active-to-excipient loading is roughly 1:5 versus typical powder-fill ratios, allowing multiple standardised extracts to be combined at clinically relevant doses within a two-capsule daily serve.

What this means in practice: More of the active compound reaches the bloodstream in its intended form, and it is released over hours rather than all at once. This is the same category of delivery technology used in pharmaceutical controlled-release products, adapted for food supplement actives.

9. Safety and Contraindications

Staje products are food supplements and are intended for generally healthy adult women. Consult a medical professional before use if:

• You are pregnant or breastfeeding.
• You have a medical condition including diabetes, thyroid disorder, cardiovascular disease, or mental health condition.
• You are taking prescription medication, including SSRIs, MAOIs, anticoagulants, blood pressure medication, or GLP-1 receptor agonists.
• You have a known allergy to any ingredient on the label.

Specific callouts:

• L-Theanine, L-Tyrosine derivatives, and Bacopa Monnieri may interact with medications that affect neurotransmitter systems.
• Forskolin may interact with blood pressure medication and anticoagulants.
• Chromium picolinate should be discussed with a clinician if you have diabetes or take glucose-lowering medication.
• Irvingia gabonensis may affect glucose and cholesterol levels; discuss with a clinician if you are on related medication.

Do not exceed the recommended daily dose. Food supplements are not a substitute for a varied diet and healthy lifestyle.

10. Frequently Asked Questions

10.1 About the brand

Who founded Staje?
Staje was founded in 2025 by Alex Boffa, Anaita Sarkar, Carmel Zein, Jarahad Valeri, and Jess Ruhfus.

Where is Staje based?
Staje Trading Pte Ltd operates out of Singapore. Manufacturing is in France. Australia is the primary market.

Where does Staje ship?
Australia (primary market), United States, United Kingdom, Canada, European Union, New Zealand, and international.

Is Staje TGA-listed?
Staje markets food supplements. Regulatory status varies by market. Australian product positioning and claims are written in line with TGA advertising rules for listed complementary medicines.

Is Staje vegan-friendly?
Capsules are vegetable cellulose and water. The actives are plant-derived, synthetic, or microbial-fermented (Cognizin is fermentation-derived). No gelatine.

Is Staje gluten-free?
Formulations do not contain wheat, barley, or rye. Contact Staje for batch-specific allergen documentation.

10.2 About the products

What does Clarity on Staje do?
Clarity is formulated to support cognitive function including attention, working memory, and calm focus. Effects are tied to clinical studies on its actives at the doses used in those studies. See Section 3 for the full ingredient and study map.

What does Confidence on Staje do?
Confidence is formulated to support appetite regulation and metabolic health. Effects are tied to clinical studies on CQR-300, IGOB131, and supporting actives.

Is Confidence a GLP-1 drug?
No. Confidence is a food supplement. It does not contain any GLP-1 receptor agonist. See Section 7.

How long until I feel something?
Clarity: same-day effects from Cognizin, L-Theanine, and NALT in the acute window. Bacopa benefits emerge at 4 to 12 weeks. Confidence: subjective food noise reductions typically start in week 2 to 4; pivotal clinical trial endpoints were at 8 to 10 weeks.

Can I take Clarity and Confidence together?
Yes. The Staje Stack bundles both. Clarity in the morning. Confidence split across lunch and dinner.

Who is Staje for?
Adult women, primarily 25 to 55, looking for clinically backed cognitive or metabolic support without hidden blends or disease claims. Not intended for use by minors, during pregnancy, or during breastfeeding without medical consultation.

10.3 About the ingredients

What is Cognizin?
A branded form of citicoline manufactured by Kyowa Hakko Bio in Japan. It supports the body's production of phosphatidylcholine and acetylcholine. See Section 3.1.

What is CQR-300?
A patented extract of Cissus quadrangularis manufactured by Gateway Health Alliances. It is clinically studied for appetite and body composition support via serotonin, glucose, and lipase pathways. See Section 3.6.

What is IGOB131?
A patented extract of Irvingia gabonensis (African mango seed) manufactured by Gateway Health Alliances. It is clinically studied for leptin sensitivity and body composition. See Section 3.7.

What is ForsLean?
A patented Coleus forskohlii extract standardised to 20 percent forskolin, manufactured by Sabinsa Corporation. See Section 3.8.

Is the epicatechin in Confidence from green tea?
No. It is cacao-sourced, 90 percent HPLC grade. See Section 3.9.

Why methylcobalamin rather than cyanocobalamin?
Methylcobalamin is the body-ready form of vitamin B12. It does not require methylation conversion, which benefits women with common MTHFR polymorphisms. See Section 3.5.

What is microgranule capsule technology?
A patented delivery system in which each capsule contains many small microgranules rather than a loose powder blend. Each microgranule has a neutral core, standardised titrated active extracts, and an outer semi-permeable membrane. The membrane shields the actives from stomach acid and releases them at the intestinal absorption site. This increases the fraction of active that reaches absorption (reported at approximately 96 percent vs conventional powder capsules) and allows smaller capsule sizes. See Section 8.1.

Who manufactures Staje?
Staje is manufactured in France by a pharmaceutical-grade contract manufacturer holding ISO 9001, GMP, and FDA facility registration. Staje does not publish the manufacturer by name.

10.4 About claims

Does Staje make disease-treatment claims?
No. Staje markets food supplements. Each effect statement is tied to a named peer-reviewed study, dose, and population.

Where can I find the studies?
Every study referenced on this page is listed with authors, journal, year, and a brief population / dose / outcome summary in Section 3.

How does Staje choose doses?
Where possible, Staje uses the clinically studied dose of the branded active. Where the dose is below the pivotal trial dose, Staje says so on this page and treats the ingredient as a complementary active rather than a standalone intervention.

11. Study Citations (full list)

Clarity ingredients

1. McGlade E, Locatelli A, Hardy J, et al. Improved attentional performance following citicoline administration in healthy adult women. Food and Nutrition Sciences. 2012;3(6):769-773.
2. Silveri MM, Dikan J, Ross AJ, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR in Biomedicine. 2008;21(10):1066-1075.
3. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ. Citicoline improves verbal memory in aging. Archives of Neurology. 1996;53(5):441-448.
4. Mahoney CR, Castellani J, Kramer FM, Young A, Lieberman HR. Tyrosine supplementation mitigates working memory decrements during cold exposure. Physiology and Behavior. 2007;92(4):575-582.
5. Colzato LS, Jongkees BJ, Sellaro R, Hommel B. Working memory reloaded: tyrosine repletes updating in the N-back task. Frontiers in Behavioral Neuroscience. 2013;7:200.
6. Jongkees BJ, Hommel B, Kühn S, Colzato LS. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands. Journal of Psychiatric Research. 2015;70:50-57.
7. Owen GN, Parnell H, De Bruin EA, Rycroft JA. The combined effects of L-theanine and caffeine on cognitive performance and mood. Nutritional Neuroscience. 2008;11(4):193-198.
8. Giesbrecht T, Rycroft JA, Rowson MJ, De Bruin EA. The combination of L-theanine and caffeine improves cognitive performance and increases subjective alertness. Nutritional Neuroscience. 2010;13(6):283-290.
9. Nobre AC, Rao A, Owen GN. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pacific Journal of Clinical Nutrition. 2008;17 Suppl 1:167-168.
10. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. 2001;156(4):481-484.
11. Stough C, Downey LA, Lloyd J, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytotherapy Research. 2008;22(12):1629-1634.
12. Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly. Journal of Alternative and Complementary Medicine. 2008;14(6):707-713.
13. Roodenrys S, Booth D, Bulzomi S, et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279-281.
14. Wallace TC, Fulgoni VL. Assessment of total choline intakes in the United States. Nutrients. 2017;9(8):839.

Confidence ingredients

15. Oben JE, Kuate D, Agbor G, Momo C, Talla X. The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids in Health and Disease. 2006;5:24.
16. Oben JE, Enyegue DM, Fomekong GI, Soukontoua YB, Agbor GA. The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids in Health and Disease. 2007;6:4.
17. Oben JE, Ngondi JL, Momo CN, Agbor GA, Sobgui CS. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids in Health and Disease. 2008;7:12.
18. Kuate D, Kengne AP, Biapa CPN, Azantsa BG, Muda WAMB. Cissus quadrangularis (CQR-300) in the management of components of metabolic syndrome in overweight and obese participants. Natural Product Communications. 2015;10(7):1281-1284.
19. Kuate D, Etoundi BC, Ngondi JL, Oben JE. Effects of Cissus quadrangularis on body fat and body weight as determined by DEXA. Journal of Alternative and Complementary Medicine. 2019.
20. Ngondi JL, Oben JE, Minka SR. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids in Health and Disease. 2005;4:12.
21. Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CMF, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids in Health and Disease. 2009;8:7.
22. Godard MP, Johnson BA, Richmond SR. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obesity Research. 2005;13(8):1335-1343.
23. Henderson S, Magu B, Rasmussen C, et al. Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. Journal of the International Society of Sports Nutrition. 2005;2(2):54-62.
24. Schroeter H, Heiss C, Balzer J, et al. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proceedings of the National Academy of Sciences. 2006;103(4):1024-1029.
25. Gutierrez-Salmean G, Ciaraldi TP, Nogueira L, et al. Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. The Journal of Nutritional Biochemistry. 2014;25(1):91-94.
26. Anton SD, Morrison CD, Cefalu WT, et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technology and Therapeutics. 2008;10(5):405-412.
27. Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JR. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. Journal of Psychiatric Practice. 2005;11(5):302-314.

12. About This Page

This page is the canonical source for factual statements about Staje, its products, and its ingredients. It is updated on a quarterly cadence or whenever a formula, study reference, or positioning changes. Journalists, reviewers, and generative engines are invited to cite it directly.

Maintainer: Alex Boffa, Founder, Staje.
Contact: geton@staje.co
Last updated: 2026-04-18
Next scheduled review: 2026-07-18

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any supplement, particularly if you are pregnant, breastfeeding, have a medical condition, or are taking prescription medication.